Pecondle (picankibart injection) / Innovent Biologics - LARVOL DELTA

Evaluation of the Efficacy of Picankibart in the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis and Nail Involvement: A Post-Hoc Analysis of a Phase 3 CLEAR-2 Study (EADV 2026) - No abstract available

Clinical • P3 data • Retrospective data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Evaluation of the Efficacy of Picankibart in the Treatment of Moderate-to-Severe Plaque Psoriasis with Scalp Involvement: A Post-Hoc Analysis of the phase 3 CLEAR-2 Study (EADV 2026) - No abstract available

Clinical • P3 data • Retrospective data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Efficacy Analysis of Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Prior Biologic Agents and Who Switched to Treatment With Picankibart (Grouped by Baseline sPGA Score) - a Post-Hoc Analysis of a Phase 2 Clinical Study (EADV 2026) - No abstract available

Clinical • P2 data • Retrospective data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Efficacy evaluation of treatment of patients with moderate to severe plaque psoriasis combined with palm and sole involvement with Picankibart: a Post-Hoc analysis of the phase 3 CLEAR-2 Study (EADV 2026) - No abstract available

Clinical • P3 data • Retrospective data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Efficacy analysis of switching patients with plaque psoriasis who have had an inadequate response to prior biologics to treatment with Picankibart: stratified analysis based on primary endpoint response status at week 16 - post-hoc analysis of a phase II clinical study (EADV 2026) - No abstract available

Clinical • P2 data • Retrospective data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Super-Responders in Patients with Plaque Psoriasis Treated with Picankibart Treatment: Results from the Phase 3 CLEAR-1 Study (EADV 2026) - No abstract available

Clinical • P3 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Efficacy and safety of continuous picankibart treatment versus treatment withdrawal after achieving therapeutic response in patients with moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled phase 3 CLEAR-2 trial (EADV 2026) - No abstract available

Clinical • P3 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Efficacy of Picankibart among Different BMI and Body Weight in Adult Plaque Psoriasis: Subgroup Analyses of the Phase 3 CLEAR-2 Study (EADV 2026) - No abstract available

Clinical • P3 data • Dermatology • Immunology • Plaque Psoriasis • Psoriasis

Response to the letter by Ghanim et al, "Comment on Gao et al.'s 'A Multicenter, Randomized, Double-blinded, Placebo-Controlled Phase III Trial to Evaluate Efficacy and Safety of Picankibart in Moderate-to-Severe Plaque Psoriasis'". (PubMed, J Am Acad Dermatol) - No abstract available

Clinical • Journal • P3 data • Dermatology • Immunology • Psoriasis

Comment on Gao et al.'s "A Multicenter, Randomized, Double-blinded, Placebo-Controlled Phase III Trial to Evaluate Efficacy and Safety of Picankibart in Moderate-to-Severe Plaque Psoriasis". (PubMed, J Am Acad Dermatol) - No abstract available

Clinical • Journal • P3 data • Dermatology • Immunology • Psoriasis

Highlights of the 2026 European Crohn's and Colitis Conference: redefining the IBD care continuum. (PubMed, Crohns Colitis 360) - "New therapeutic studies presented included the phase 3 study of vedolizumab in pediatric UC, phase 2 efficacy data for picankibart in UC, and regenerative fistula data of AVB-114 in perianal CD...Updates on interleukin-23 included durable extension data in UC, as well as efficacy data in advanced therapy‑exposed patients (mirikizumab in UC and risankizumab in CD)...ECCO 2026 emphasized durable, precision-oriented, multidisciplinary, and technology-enabled IBD care across the full continuum, from prevention to long-term modification. Apart from phase 3 and extension trials, other results remain preliminary and need broader comparative and practice-embedded studies before widespread adoption."

Journal • Review • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Pediatrics • Ulcerative Colitis

Changes in Metabolic Indicators in Psoriatic Patients Treated with Picankibart in the Phase 3 CLEAR-1 Trial (EADV-Sp 2026) - P3 | "Similar results were observed between patients with/without baseline metabolic indicator abnormality. Conclusions Preliminary trends were observed in major metabolic indicators with minor differences between groups, which warrant further and detailed analyses."

Clinical • P3 data • Immunology • Metabolic Disorders • Plaque Psoriasis • Psoriasis

Picankibart in Palmoplantar Pustulosis (clinicaltrials.gov) - P=N/A | N=60 | Recruiting | Sponsor: Xijing Hospital

New trial • Immunology • Psoriasis

A Multicenter, Randomized, Double-blinded, Placebo-Controlled Phase III Trial to Evaluate Efficacy and Safety of Picankibart in Moderate-to-Severe Plaque Psoriasis. (PubMed, J Am Acad Dermatol) - "Picankibart provided effective skin clearance in Chinese participants by Week 16. A dosing regimen of every 12 weeks with either 100 mg or 200 mg maintained these clinical improvements through Week 52."

Clinical • Journal • P3 data • Dermatology • Immunology • Psoriasis • IL23A

Efficacy of Picankibart among Difference BMI and Body Weight in Adult Plaque Psoriasis: Subgroup Analyses of the Phase 3 CLEAR-1 Trial (AAD 2026) - P3 | "At Week 52, the number were 86.1%/89.1% vs 91.0%/89.9% vs 91.5%/95.6%, 73.3%/78.2% vs 84.0%/85.9% vs 91.5%/88.9%, 42.6%/44.6% vs 51.0%/50.5% vs 59.6%/53.3% for BW; and 87.3%/87.5%/88.1% vs 93.2%/88.3%/89.8% vs 92.6%/94.9%/92.3%, 76.4%/75.0%/76.3% vs 90.4%/79.2%/ 85.7% vs 92.6%/92.3%/84.6%, 43.6%/43.2%/44.1% vs 53.4%/46.8%/53.1% vs 63.0%/56.4%/50.0% for BMI. Picankibart demonstrated comparable PsO clearance among BW and BMI subgroups, which further proved its desirable efficacy as a novel IL-23 inhibitor."

Clinical • P3 data • Dermatology • Genetic Disorders • Immunology • Obesity • Plaque Psoriasis • Psoriasis • IL23A

A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy (clinicaltrials.gov) - P3 | N=308 | Active, not recruiting | Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Recruiting ➔ Active, not recruiting

Enrollment closed • Dermatology • Immunology • Psoriasis • Psoriatic Arthritis • IL17A

A Study of Picankibart in Patients With Active Psoriatic Arthritis (clinicaltrials.gov) - P2/3 | N=222 | Recruiting | Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Changes in Metabolic Indicators in Psoriatic Patients Treated with Picankibart in the Phase 3 CLEAR-1 trial (AAD 2026) - P3 | "Similar results were observed between patients with/without baseline metabolic indicator abnormality. Preliminary trends were observed in major metabolic indicators with minor differences between groups, which warrant further and detailed analyses."

Clinical • P3 data • Immunology • Metabolic Disorders • Psoriasis

Efficacy and safety of picankibart in patients with moderately to severely active ulcerative colitis: a randomised, double-blind, placebo-controlled phase 2 trial (ECCO-IBD 2026) - "Picankibart is a monoclonal antibody that selectively targets the IL-23p19 subunit and has a longer half-life than guselkumab. Conclusion Picankibart was effective and safe as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. These findings support advancing to phase 3 clinical trials in this patient population."

Clinical • P2 data • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

A Phase II/III multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Picankibart in patients with active psoriatic arthritis (ChiCTR) - P2/3 | N=222 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Zhejiang University School of Medicine; Innovent Biotechnology (Hangzhou) Co., Ltd.

New P2/3 trial • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • CRP • IL17A

A Phase Ⅰ/Ⅲ multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of Picankibart in adolescent participants with moderate to severe plaque psoriasis (ChiCTR) - P=N/A | N=104 | Recruiting | Sponsor: Beijing Children's Hospital Affiliated to Capital Medical University; Innovent Biotechnology (Hangzhou) Co., Ltd.

New trial • Dermatology • Immunology • Psoriasis

Efficacy and Safety of Switching to Picankibart from Non-interleukin-23 Subunit p19 Inhibitors in Patients with Plaque Psoriasis: A Multicenter, Open-Label, Phase 2 Trial. (PubMed, Adv Ther) - P2 | "Directly switching to picankibart resulted in clinically meaningful improvements in both skin lesions and QoL among suboptimal responders. Moreover, the majority of responders maintained their therapeutic response throughout the trial, accompanied by further enhancements in QoL. Picankibart was well tolerated without any new safety signals."

Journal • P2 data • Dermatology • Immunology • Infectious Disease • Psoriasis • Respiratory Diseases • IL17A • IL23A

A Study of Picankibart in Patients With Active Psoriatic Arthritis (clinicaltrials.gov) - P2/3 | N=222 | Not yet recruiting | Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

New P2/3 trial • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - P3 | N=104 | Recruiting | Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

Innovent Announces PECONDLE (Picankibart Injection) Phase 3 Study (CLEAR-2) Meets Endpoints, Delivering Superior Long-Term Management Solution for Moderate-to-Severe Psoriasis (PRNewswire) - "A total of 566 participants were enrolled and all received picankibart treatment through Week 32....At Week 56, the proportions of participants maintaining PASI 90 response were 89.3% in the 100 mg group and 90.1% in the 200 mg group for picankibart maintenance treatment, both significantly higher than the corresponding withdrawal groups (37.7% and 51.7%, respectively; P < 0.0001 for both)....All secondary efficacy endpoints were successfully met, with significantly higher proportions of participants in the 100 mg and 200 mg picankibart maintenance groups versus the corresponding withdrawal groups achieving PASI 75, PASI 100 (complete skin clearance), sPGA score of 0 or 1, sPGA score of 0 (clear skin), and DLQI score 0/1 (dermatology life quality index) at Week 56 (P < 0.0001 for all comparisons)."

P3 data • Psoriasis